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pared to controls (48.5±6.2%), LF HRV was significantly reduced at D15
(31.6±5.4%) but not at D30 (58.2±16.2%) without change in HF. LF/HF ratio
was lower in 6OH-DA treated mice at D15 (0.5±0.1 vs 1.3±0.2 in controls)
but not at D30 (1.6±0.3). At D15, 6-OH-DA hearts exhibited mild structural
abnormalities with wavy cardiomyocyte appearance in septum. At D30, histo-
logical abnormalities were diffuse with myocytes intersecting at various angles
with bundles wavy appearance. Variability in cell size with anisocaryosis,
attenuated myocytes with perinuclear halo and shaped nuclei were observed.
No inflammation, interstitial fibrosis or necrosis was noticed.
 
In conclusion
 
, this study suggests that heart denervation induces myocardial
tissue disorganization. Relationship between these changes and sympathetic
nerve destruction and/or catecholamine depletion remains to be elucidated.
Apart from physiological significance, these results also bring new structural
basis to explain increased risk of cardiac disease during autonomic failure.
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Introduction:
 
 Latest generation continuous flow left ventricular assist
devices (LVADs) have been proposed as an alternative to heart transplantation
for end-stage heart failure. However, postoperative right ventricle (RV) dys-
function remains common and has a negative impact on prognosis. Purpose of
our study was to identify echocardiographic or hemodynamic parameters that
could predict early RV failure after LVAD implantation in patients with biven-
tricular dysfunction.
 
Methods:
 
 Fourteen patients with biventricular dysfunction who have been
evaluated for LVAD implantation were included. Right and left ventricular dys-
function were respectively defined as: tricuspid annular plane excursion < 16 mm
(TAPSE) and LV ejection fraction < 35%. In all patients, preoperative measure-
ments were obtained at rest. In 7 patients, right heart catheterization was per-
formed simultaneously with increasing doses of dobutamine (15
 
γ
 
/Kg/min).
Primary endpoint was death caused by right ventricle systolic dysfunction or need
for right ventricle mechanical support within 30 days after surgery (RVSD+).
 
Results:
 
 Mean recipient age was 58±7 years. Primary end-point (RVSD+)
was noted in five patients. Preoperative demographic, echocardiographic and
hemodynamic data were similar between RVSD+ and RVSD- patients (Table).
Percent increase of TAPSE and systolic PAP between basal and high dob-
utamine dose was significantly lower in RVSD+ than in RVSD- patients.
 
Conclusion:
 
 Percent increase of TAPSE and systolic PAP induced by high
dose dobutamine infusion might be two interesting criteria to assess RV con-
tractile reserve and predict RV outcome after LVAD implantation in patient
with biventricular dysfunction.
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Rationale:
 
 Heart failure (HF) with preserved LVEF has been individual-
ized in the recent years as a specific entity, with different mechanisms, special
baseline characteristics, a poor prognosis and no clearly recognized treatment.
Recent papers have focused on patients with LVEF between 40% and 50%
who could not be clearly classified as patients with reduced or preserved
LVEF. 
 
Objectives:
 
 to describe the management care of patients according to
the LVEF with special emphasis on patients belonging to the "grey zone".
 
Methods:
 
 Cross sectional observational survey with retrospective collec-
tion of data at hospital discharge. Patients must have been diagnosed with HF
and have been hospitalised for HF within the previous 18 months. Patients are
classified according to the LVEF at hospital discharge. 
 
Results:
 
 412 French
outhospital cardiologists included 1 452 patients meeting the inclusion criteria.
Management care at hospital discharge according to LVEF (known in 1 408
patients) is detailed below.
 
Conclusion:
 
 This is the first French survey in patients managed by cardi-
ologists after hospital discharge for HF. Cardiologists mainly care for patients
with low LVEF. Treatment at hospital discharge is optimal regarding medical
classes, with poor differences according to EF. Rate of betablockers and ACEI
is quite high in the group with EF > 50%, even if it is lower than in the groups
with low EF. As a whole, in France, the 40-50% group is managed as the <
40% one.
 
Table. Drug therapy according to LVEF 
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Background:
 
 Alterations of diffusion lung carbon monoxide (DLco) and
alveolar-capillary membrane gas conduction (Dm) are associated with poor
prognosis in patients with heart failure (HF) or stable coronary artery disease
(CAD) even when LV systolic function is preserved. However, the impact of
LV function on diffusing lung capacity is poorly understood.
 
Methods and Results:
 
 Twelve healthy subjects were compared to 19
patients with stable HF and LV systolic dysfunction and to 12 patients with
stable CAD and preserved LV systolic function. Diffusing lung capacity was
assessed by DLco and Dm, using single breath technique and Roughton-For-
 
 
Baseline Measurement 
(n=14)
Change after 
Dobutamine infusion,% 
(n=7)
 RVSD- RVSD+ p RVSD- RVSD+ p
N
 
9 5  3 4  
 
TAPSE, mm
 
14 ± 2 14 ± 2 0.9 55 ± 5 26 ± 2 0.03
 
Systolic PAP, 
mmHg
 
51 ± 7 53 ± 6 0.8 42 ± 8 4 ± 7 0.05
 
Cardiac Output, 
l/min
 
3.3 ± 0.5 3.5 ± 0.5 0.9 87 ± 10 93 ± 47 0.7
 
Pulm Vasc Res, 
Wood
 
3.9 ± 1 4.3 ± 1 0.6 2 ± 41 -36 ± 7 0.8
 
 LVEF<40% 
n=792
LVEF 40-50% 
n=366
LVEF>50% 
n=250 p
ACEI/ARB
 
91% 90%† 83% 0,002
 
Betablocker
 
78% 76%† 64% <0,0001
 
Loop diuretics
 
90% 83%* 82% <0,001
 
Spironolactone
 
29% 19%* 21% 0,0003
 
Digoxin 
 
16% 15% 21% 0,15
 
Calcium antagonists
 
9% 18%†* 27% <0,0001
 
Anticoagulants
 
43% 41% 43% 0,64
 
p by ANOVA with Bonferroni correction; 
† p<0.05 for comparisons between “grey zone” and LVEF>50%; 
* p<0.05 for comparisons between “grey zone” and LVEF<40%. 
 © Elsevier Masson SAS. All rights reserved.
 
 
26
 
Archives of Cardiovascular Diseases Supplements (2010) 2, 22-38
 
ster method. Comprehensive transthoracic echocardiography was performed to
evaluate LV ejection fraction (EF), Sa velocity, global longitudinal strain
(GLS), E and Ea velocities and E/Ea ratio. Demographic and clinical data
were similar between the 3 groups. However, HF group were significantly
older than control or CAD groups (65±7 vs. 54±12 or 56±7yrs, p<0.01). Com-
pared to control subjects, patients with CAD or HF had lower DLco and Dm
(33±6 vs. 25±6 vs. 20.5±6, p<0.01; 55±17 vs. 37±10 vs. 30±11ml.min
 
-1
 
.mmHg
 
-1
 
,
p<0.01). In the whole cohort, DLco was correlated with systolic and diastolic
parameters (LVEF: r=0.47, p=0.001; GLS: r=0.35, p=0.02; Sa: r=0.49,
p=0.0007; E/Ea: r=-0.30, p=0.05; Ea: r=0.51, p=0.0006). Similar results were
found with Dm (LVEF: r=0.44, p=0.004; GLS: r=0.33, p=0.03; Sa: r=0.47,
p=0.001 and E/Ea: r=-0.36, p=0.02; Ea: r=0.49, p=0.0009). On multivariate
analysis, after adjustment for age, sex and BMI, independent predictors of
DLco as well as Dm were Ea (r
 
2
 
=0.27, p=0.0006; r
 
2
 
=0.25, p=0.001) and
LVEF<50% (r
 
2
 
=0.08, p=0.03; r
 
2
 
=0.07, p=0.03).
 
Conclusion:
 
 Reduced diffusing lung capacity is related to both LV dias-
tolic and systolic dysfunctions. Ea-wave velocity is the strongest determinant
of this alteration, emphasizing the crucial role of LV relaxation. These find-
ings could explain diffusing lung abnormalities observed in patients with pre-
served LV systolic function.
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Cardiac resynchronization therapy (CRT) is an effective treatment of
advanced heart failure (HF). Recent studies showed a positive effect of CRT
on HF symptoms, left ventricular ejection function (EF,%), reduction of hos-
pitalizations and survival. However, most studies evaluated clinical and
echocardiographic response to CRT after a limited follow-up (ranging from 6
to 12 months).
Thus we evaluated clinical and functional response to CRT in HF patients
(pts) after a longer follow-up period (up to 3 years, ys).
We enrolled 75 HF outpts with CRT indication [30% females, mean age
67.9±12.6 ys, mean NYHA class 2.8±0.7, mean EF 25.7±8.1, HF aetiology:
44% coronary artery disease (CAD), 43% dilated cardiomyopathy (DCM), 6%
hypertensive cardiomyopathy (HT), 7% valvular disease (V)]. All were evalu-
ated by means of ECG, echocardiography, NYHA functional class before CRT
device implant and re-evaluated after 1 (95% of pts), 2 (80% of pts), and 3
(45% of pts) ys.
After 1 y, NYHA significantly improved (from 2.8±0.7 to 2.3±0.6,
p<0.0001), as well as EF (from 25.7±8.1 to 30.1±9.0, p=0.005). This improve-
ment was maintained after 2 ys (NYHA 2.3±0.6, EF 31.8±9.4) and 3 ys
(NYHA 2.2±0.6, EF 33.4±10.2). Overall, we registered 8 deaths, of which 2
(2.7%) after 1 y, 3 (4%) after 2 ys and 3 (4%) after 3 ys. Dividing pts on the
basis of HF aetiology, after 1 y all pts presented a significant improvement,
while further on DCM pts showed a steady increase of EF (basal 22.9±7.8,
after 1 y 28.8±9.5, after 2 ys 31.3±11.1 and after 3 ys 35.4±13.3), while CAD
pts showed stabilization of EF on the first y values (basal 26.3±7.3, after 1 y
29.5±7.4, after 2 ys 29.7±6.3 and after 3 ys 29.9±5.2). Echocardiographic
response to CRT in terms of EF is clearly evident after 1 y and remains
improved after 2 and also 3 ys, with a not significant trend to further improve
in DCM. All pts significantly improved NYHA within the first y. Benefit
deriving from CRT is maintained during long term follow-up.
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Background:
 
 Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is an inherited cardiac disease, usually an autosomal dominant dis-
order, that may lead to sudden death, particularly in young people and athletes.
Five desmosomal genes have been recently implicated in ARVD/C: JUP, DSP,
PKP2, DSG2 and DSC2. We performed a systematic screening of these genes
in a large population to address the potential clinical impact of genotyping.
 
Methods and results: 
 
Direct sequencing of the 5 predefined genes was per-
formed in 135 unrelated patients with ARVD/C meeting the international Task
Force criteria. We identified 66 disease-causing mutations in 61 patients (45%).
Distribution of genes was 31% (41/135) for PKP2, 10% (14/135) for DSG2,
4% (6/135) for DSP, 1% (2/135) for DSC2 and 0% for JUP. The identification
rate was not related to age of patients nor familial context. In 48% (32/66) a
mutation was identified in a single family or individual (private mutation). In
addition, a genetic variant of unknown significance was identified in additional
10 patients (7%). Finally, complex genetic status with double mutations was
identified in 4% of patients and multiple mutations tend to be associated with
a more severe phenotype (namely more frequent cardiac arrest).
 
Conclusions:
 
 We performed the most comprehensive screening of desmo-
somal genes in the largest population of ARVD/C patients reported until now.
A molecular diagnosis strategy can be deduced, requiring however exhaustive
genetic screening of four desmosomal genes, with the possible identification
of genetic variants of unknown significance. The relatively high success rate
of genotyping in ARVD/C suggests the possible use of genetic testing as a
diagnostic tool, with potential important impact for early diagnosis in border-
line patients and relatives.
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Aims: Dilated Cardiomyopathy (DCM) is familial in about 30% of cases,
and mutations have been identified in several genes. However, in a majority
of familial cases the responsible genes are still to be discovered. The ANKRD1
gene is overexpressed in heart failure in human and animal models. The
encoded protein CARP interacts with partners such as Myopalladin or Titin,
previously shown to be involved in DCM. We hypothesised that mutations in
ANKRD1 could be responsible for DCM.
Methods and Results: We sequenced the coding region of ANKRD1 from
231 independent DCM cases. We identified 5 missense mutations (3 sporadic
and 2 familial) absent from 400 controls and affecting highly conserved resi-
dues. Expression of the mutant CARP proteins after transfection in rat neonate
cardiomyocytes indicated that most of them led to both significant less
repressor activity measured in a reporter gene assay and greater phenylephrin
induced hypertrophy suggesting altered function of CARP mutant proteins.
Conclusion: Based on genetic and functional analysis of CARP mutations,
we have identified ANKRD1 as a new gene associated with DCM, accounting
for about 2% of cases.
